| 生物活性 |
JR4-187 is an orally active copper-dependent anticancer agent that downregulates genes involved in oxidative phosphorylation, MYC targets, and E2F targets while upregulating genes involved in TNF-α signaling, p53 pathway, and KRAS signaling, and downregulates CTR1 protein; it induces ROS production, apoptosis, and copper-dependent cytotoxicity, exhibits selective cytotoxicity against KRAS-mutant cancer cells, is well tolerated in mouse models of pancreatic cancer, and can be used for research on pancreatic ductal adenocarcinoma, colon cancer, rectal cancer, and other cancers. |
体外研究 (In Vitro) |
JR4-187 (2 μM; 24 h) 可下调 HCT116 细胞中参与氧化磷酸化、MYC 靶标及 E2F 靶标的基因,同时上调参与 TNF-α 信号通路、p53 通路及 KRAS 信号通路的基因。 JR4-187 (2.5-15 μM; 4-24 h) 可显著下调 HCT116、MIA PaCa-2、PANC1 和 BXPC3 细胞中 MYC、NDUFS7 蛋白的表达。 JR4-187 (0.03-1 μM; 6 days) 在 HCT116 结肠癌细胞中可产生细胞毒性作用 (与 Danazol (MS-P50679)、Metformin (MS-K91034)、IACS-010759 (MS-M78469)、Rotenone (MS-D42728)、DX2-201 (MS-W96249)、DX3-213B (MS-K50640)、AGB-374 联用)、拮抗作用 (与 MYCi361 (MS-Z07152)、10058-F4 (MS-D52088)、MYCMI-6 (MS-Z64494) 联用)。 JR4-187 (10 μM; 24 h) 可显著下调 HCT116 和 MIA PaCa-2 细胞中 CTR1 蛋白的表达。 JR4-187 (2.5 μM; 24 h) 与 5 μM AGB-374 (MS-S62348) 联合作用可在 HCT116 结肠癌细胞中协同下调 MYC 和 NDUFS7 的蛋白表达。 JR4-187 (Compound 39) 可强效抑制 KRAS 突变型胰腺癌和结肠癌细胞的增殖,在 SU.86.86 细胞 (IC50 = 0.8 μM) 和 MIA PaCa-2 细胞 (IC50 = 1.9 μM) 中活性最高,在 KRAS 野生型 BxPC-3 细胞中活性较低。 JR4-187 (0-10 μM; 6 days) 具有铜依赖性细胞毒性,在 MIA PaCa-2 和 HCT116 细胞中与 CuSO4 表现出强协同作用,且在铜螯合剂 TTM (MS-R55382 ) 存在下活性降低。 JR4-187 (0-5 μM; 6 days) 与 COX2 抑制剂 Celecoxib (MS-N33697) 和 Rofecoxib (MS-T31275) 在抑制 HCT116、MIA PaCa-2 和 BxPC-3 细胞的集落形成方面表现出强协同作用。 JR4-187 (0-1 μM; 6 days) 在 HCT116 和 MIA PaCa-2 细胞中可诱导 ROS 依赖性细胞死亡。 JR4-187 (0-10 μM; 1-6 days) 可通过细胞凋亡和坏死性凋亡部分诱导 MIA PaCa-2 和 HCT116 细胞死亡。
Western Blot Analysis
| Cell Line: |
HCT116 human colon cancer cells |
| Concentration: |
10 μM |
| Incubation Time: |
4 h; 24 h |
| Result: |
Significantly downregulated MYC protein levels relative to control cells. |
Western Blot Analysis
| Cell Line: |
MIA PaCa-2 and BXPC3 human pancreatic cancer cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Decreased MYC protein abundance in both MIA PaCa-2 and BXPC3 cells. |
Western Blot Analysis
| Cell Line: |
HCT116 human colon cancer cells, MIA PaCa-2 and PANC1 human pancreatic cancer cells |
| Concentration: |
2.5, 5, 7.5, 10, 15 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a dose-dependent reduction in MYC protein levels in HCT116, MIA PaCa-2, and PANC1 cells.\nCaused a dose-dependent reduction in NDUFS7 protein levels in HCT116, MIA PaCa-2, and PANC1 cells. |
Cell Cytotoxicity Assay
| Cell Line: |
HCT116 human colon cancer cells |
| Concentration: |
0.03, 0.1, 0.3, 1 μM |
| Incubation Time: |
6 days |
| Result: |
Showed strong cytotoxic synergy with Danazol. Showed strong antagonism with MYCi361, 10058-F4, and MYCMI-6. Showed no significant interaction with 10074-G5. Showed significant synergy with metformin, IACS-010759, and Rotenone. Showed weak synergy with 2-DG. Showed significant synergy with DX2-201, DX3-213B, and AGB-374. |
Western Blot Analysis
| Cell Line: |
HCT116 human colon cancer cells and MIA PaCa-2 human pancreatic cancer cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a marked decrease in CTR1 protein levels in both HCT116 and MIA PaCa-2 cells, with a log10 fold change of ~-0.3 in HCT116 cells and ~-0.15 in MIA PaCa-2 cells. |
Western Blot Analysis
| Cell Line: |
HCT116 human colon cancer cells |
| Concentration: |
2.5 μM (alone and in combination with 5 μM AGB-374) |
| Incubation Time: |
24 h |
| Result: |
Led to synergistic downregulation of both MYC and NDUFS7 protein levels in HCT116 cells, compared to monotherapy with either agent. |
Cell Cytotoxicity Assay
| Cell Line: |
MIA PaCa-2, HCT116 |
| Concentration: |
0, 0.018, 0.05, 0.16, 0.5 μM/0, 0.03, 0.1, 0.3, 1 μM/0. 0.3. 1.1, 3.3, 10 μM |
| Incubation Time: |
6 days |
| Result: |
Showed strong synergy with copper sulfate (CuSO4) in both cell lines, as measured by the HSA model in Combenefit software. Exhibited significantly reduced cytotoxic activity when combined with copper chelator ammonium Tetrathiomolybdate (TTM). |
Cell Proliferation Assay
| Cell Line: |
HCT116, MIA PaCa-2, BxPC-3 |
| Concentration: |
0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Celecoxib); 0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2 with Celecoxib; MIA PaCa-2 with Rotecoxib); 0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Rotecoxib); 0, 0.18, 0.5, 1.6, 5 μM ( BxPC-3 with Celecoxib) |
| Incubation Time: |
6 days |
| Result: |
Showed strong synergy with celecoxib across all three cell lines, as measured by the HSA model in Combenefit software. Exhibited strong synergy with rotecoxib in HCT116 and MIA PaCa-2 cells, as measured by the HSA model in Combenefit software. |
Cell Cytotoxicity Assay
| Cell Line: |
HCT116, MIA PaCa-2 |
| Concentration: |
0, 0.03, 0.1, 0.3, 1 μM (HCT116); 0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2) |
| Incubation Time: |
6 days |
| Result: |
Induced cell death that was rescued by pretreatment with ROS scavenger N-acetyl cysteine (NAC) in both cell lines. |
Cell Cytotoxicity Assay
| Cell Line: |
MIA PaCa-2, HCT116 |
| Concentration: |
0, 0.018, 0.05, 0.16, 0.5 μM (MIA PaCa-2 with Z-VAD-FMK; MIA PaCa-2 with Necrostatin-1); 0, 0.03, 0.1, 0.3, 1 μM (HCT116 with Z-VAD-FMK); 0, 0.07, 0.2, 0.6, 2 μM (HCT116 with necrostatin-1); 10 μM (WB for apoptosis markers); 10 μM (WB for necroptosis markers) |
| Incubation Time: |
6 days/48 h (WB for apoptosis markers); 48 h (WB for necroptosis markers) |
| Result: |
Induced cell death that was partially rescued by apoptosis inhibitor Z-VAD-FMK and necroptosis inhibitor necrostatin-1 in both cell lines. Increased cleaved PARP, cleaved caspase-9, cleaved caspase-3 (apoptosis markers) in cells treated for 48 h, as confirmed by Western blot analysis. Increased phospho-RIP3 (necroptosis marker) in cells treated for 1 h, as confirmed by Western blot analysis. |
|